RxDoctor Payments DataLook up a doctor →

Seth Greenky, MD

Adult Reconstructive Orthopaedic Surgery · Liverpool, NYNPI 1225093982

Payments from drug & device makers

$584,057in general payments, 2019–2025

Across 456 payments — averaging $1280.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Smith+Nephew$252K
  • Zimmer Biomet$130K
  • Stryker$110K
  • Limacorporate S.p.a.$55K
  • Encore Medical, LP$26K
  • Lima USA, Inc.$9K
  • plus $1K from 15 others
$15,242in research payments, 2019–2025

Across 2 payments — averaging $7621.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Limacorporate S.p.a.$14K
  • Stryker$750

What the payments were for

  • Consulting fees$61,22560%
  • Travel & lodging$27,26427%
  • Food & beverage$13,08813%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$584,057 in reported general payments places this provider in the 85th percentile of 85 adult reconstructive orthopaedic surgery providers in New York.

See all adult reconstructive orthopaedic surgery providers in New York

Medicare billing

Part B allowed, 2024
$375,567
Medicare patients
858
Services billed
14,484

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban27$7,235
Celecoxib276$4,120
Naloxone Hcl24$2,999
XareltoRivaroxaban14$2,955
Pregabalin80$1,856
Oxycodone Hcl215$1,136
Ketorolac Tromethamine88$726
Meloxicam274$628
Diclofenac Sodium33$302
Amoxicillin301$287
Doxycycline Hyclate18$160
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen16$146
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen23$129
Clindamycin Hcl21$127
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim11$97

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$511$2,95514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 85 adult reconstructive orthopaedic surgery providers in New York.

Other adult reconstructive orthopaedic surgery in Liverpool

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →